Epidermal growth factor biological activities

Hughes, WE, Larijani, B and Parker, PJ (2002) Detecting protein-phosphoUpid interactions. Epidermal growth factor-induced activation of phospholipase Dlb in situ. Journal of Biological Chemistry, 277, 22974—22979. 

Bevacizumab, a humanized IgG and cetuximab, a chimeric IgGx, are currently marketed in the US for treatment of metastatic colorectal cancer [92, 93]. Bevacizumab neutralizes the biological activity of vascular endothelial growth factor (VEGF), while cetuximab binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Bevacizumab, in combination with IV 5-fluorouracil (5-FU) -based chemotherapy, is indicated for first-line treatment of metastatic colorectal cancer, whereas cetuximab is used in patients refractory to or intolerant to irinotecan-based chemotherapy. The clinical pharmacokinetics of cetuximab are discussed in detail in Chapter 14. 

Multiple mechanisms are probably involved in immune-modulating effects of AMPs. A variety of receptors has been described for cathelicidins, however, only one biological function, that of LL-37-mediated chemotaxis of human peripheral blood leukocytes, is associated with a known receptor (formyl peptide receptor like 1), [187]. Human BD-2 recruits mast cells and LL-37 activates epithelial cells through at least 2 classes of receptors [183,202], LL-37 transactivates epidermal growth factor receptor (EGFR) and promotes the release of IL-ip [203], and LL-37-induced maturation of LPS-primed monocytes requires the P2X(7)... 

Bursi, R., Verwer, P., Gazit, A., Beccari, A.R., Uccello Beretta, G., Balzano, F. and Guccione, S. (2001) From molecular spectra to biological activities a comparative spectra analysis (CoSA) study on epidermal growth factor receptor protein tyrosine kinase inhibitors, in Rational Approaches to Drug Design (eds H.-D. Hdltje and W. Sippl), Prous Science, Barcelona, Spain, pp. 211-213. 

Lee H. and Parg, T. G., Preparation and characterization of mono-pegylated epidermal growth factor evaluation of in vitro biologic activity, Pharmaceutical Research, 19, 845, 2002. 

Following detection of the antiviral activity of hypericin 1 (see above), a number of observations have suggested that this compound may as well represent a potential anti-cancer therapy. These biological properties include the light-dependent inhibition of protein kinase C [142], the photosensitized inhibition of mitochondrial succinoxidase [143], and the photoinduced inhibition of epidermal growth factor receptor (EGF-R) tyrosine kinase activity [144]. 

Bost, F., McKay, R., Dean, N., and Mercola, D., The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells, J. Biological Chem., 272, 33422-33429, 1997. 

---